Gefitinib

Common brands: Iressa, Tagrisso, Carboplatin, Kyxata, Pemetrexed

Top reporter: Astrazeneca Pharmaceuticals Lp

Kinase Inhibitor [EPC]Platinum-based Drug [EPC]Microtubule Inhibitor [EPC]Folate Analog Metabolic Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
8,949
Total Reports
2,778
Serious Reports
1,949
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.78%)

Patient Demographics

Male
3,241
Female
4,805

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Gefitinib.

# Reaction Reports % of Total
1 MALIGNANT NEOPLASM PROGRESSION 1,817
15.5%
2 DRUG RESISTANCE 1,249
10.6%
3 DIARRHOEA 901
7.7%
4 DEATH 755
6.4%
5 RASH 640
5.5%
6 DISEASE PROGRESSION 458
3.9%
7 INTERSTITIAL LUNG DISEASE 420
3.6%
8 NAUSEA 378
3.2%
9 METASTASES TO CENTRAL NERVOUS SYSTEM 376
3.2%
10 DYSPNOEA 332
2.8%
11 VOMITING 325
2.8%
12 DRUG INEFFECTIVE 298
2.5%
13 PYREXIA 271
2.3%
14 PNEUMONIA 269
2.3%
15 ACQUIRED GENE MUTATION 258
2.2%
16 HEPATIC FUNCTION ABNORMAL 247
2.1%
17 PLEURAL EFFUSION 243
2.1%
18 FATIGUE 240
2.0%
19 DECREASED APPETITE 231
2.0%
20 LUNG DISORDER 218
1.9%
21 ASTHENIA 207
1.8%
22 OFF LABEL USE 205
1.7%
23 COUGH 193
1.6%
24 DRY SKIN 193
1.6%
25 METASTASES TO BONE 180
1.5%
26 DEHYDRATION 174
1.5%
27 PRURITUS 174
1.5%
28 LIVER DISORDER 165
1.4%
29 ANAEMIA 163
1.4%
30 WEIGHT DECREASED 153
1.3%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.